Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
ChemoMetec A/S (CHEMM.CO)
Allerød, DK
Headquartered in Allerød, Denmark, and established in 1997, ChemoMetec A/S focuses on the design, production, and worldwide distribution of analytical instruments for cell enumeration and analysis. Their sophisticated solutions are utilized across diverse fields, including cell-based therapeutics, oncology and stem cell research, pharmaceutical development and manufacturing, along with quality assurance for animal semen and beer. The company's product offerings feature a range of NucleoCounter devices, such as the NC-3000 advanced image cytometer, the NC-250 automated cell analyzer, and the consistent NC-202 and NC-200 automated cell counters for viability assessment. Specialized counters include the NucleoCounter SP-100 for automated sperm cell analysis in animal production, the SCC-100 for measuring somatic cells in milk samples, and the YC-100 for total count and viability of yeast cells. Beyond equipment, they also supply vital consumables like cassettes and reagents, various accessories such as software and cables, and offer extensive service and validation plans.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +5.28% | +9.52% | +17.19% | -10.80% | -52.08% | -44.40% | -25.89% | -21.42% | -50.00% | +1,036.36% | +1,604.55% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 4 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%+21.5% ★ Q4'25: +24.6% (vs Q4'23)
-
EPS growth Medical - Devices: +28.5%+36.8% ★ Q4'25: +33.0% (vs Q4'23)
-
FCF margin FCF growth · Medical - Devices: +30.9%+34.1% ★ Q4'25: +31.8% (vs Q4'23)
-
EBIT margin Medical - Devices: +6.2%+47.7% ★ Q4'25: +49.2% (vs Q4'23)
-
ROIC Medical - Devices: +3.3%+54.4% ★ Q4'25: +98.2% (vs Q4'23)
-
Share dilution Medical - Devices: 0.0%+0.0% ★ Q4'25: -0.1% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×0.03× ★ Q4'25: 0.02× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Jun 2022 actual |
Jun 2023 actual |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 4 Rev. Ana. 4 EPS Ana. |
Jun 2027 4 Rev. Ana. 4 EPS Ana. |
Jun 2028 4 Rev. Ana. 4 EPS Ana. |
Jun 2029 2 Rev. Ana. 1 EPS Ana. |
Jun 2030 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
428.39M
est: 426.05M (+0.6%)
|
444.40M
est: 449.00M (-1.0%)
|
407.87M
est: 407.00M (+0.2%)
|
495.57M
est: 496.00M (-0.1%)
|
514.02M
510.34M – 516.25M
+3.6% YoY
|
563.98M
543.39M – 582.13M
+9.7% YoY
|
653.88M
650.65M – 657.12M
+15.9% YoY
|
709.00M
693.00M – 722.44M
+8.4% YoY
|
793.00M
775.11M – 808.03M
+11.8% YoY
|
| EBITDA |
218.54M
est: 210.47M (+3.8%)
|
245.38M
est: 221.81M (+10.6%)
|
186.59M
est: 201.06M (-7.2%)
|
247.68M
est: 245.02M (+1.1%)
|
253.93M
252.11M – 255.03M
+3.6% YoY
|
278.61M
268.44M – 287.57M
+9.7% YoY
|
323.02M
321.42M – 324.62M
+15.9% YoY
|
350.25M
342.34M – 356.89M
+8.4% YoY
|
391.74M
382.90M – 399.17M
+11.8% YoY
|
| EBIT |
204.70M
est: 197.15M (+3.8%)
|
231.45M
est: 207.77M (+11.4%)
|
176.77M
est: 188.33M (-6.1%)
|
236.52M
est: 229.52M (+3.1%)
|
237.85M
236.15M – 238.88M
+3.6% YoY
|
260.97M
251.45M – 269.37M
+9.7% YoY
|
302.57M
301.07M – 304.07M
+15.9% YoY
|
328.08M
320.68M – 334.30M
+8.4% YoY
|
366.95M
358.67M – 373.90M
+11.8% YoY
|
| Net Income |
159.47M
est: 157.00M (+1.6%)
|
178.67M
est: 182.73M (-2.2%)
|
136.28M
est: 136.28M (+0.0%)
|
186.41M
est: 186.41M (+0.0%)
|
199.78M
184.61M – 208.81M
+7.2% YoY
|
226.75M
188.83M – 241.01M
+13.5% YoY
|
280.40M
256.24M – 293.85M
+23.7% YoY
|
278.44M
270.27M – 285.30M
-0.7% YoY
|
313.24M
304.06M – 320.96M
+12.5% YoY
|
| SGA |
40.40M
est: 68.69M (-41.2%)
|
44.02M
est: 72.39M (-39.2%)
|
45.19M
est: 65.62M (-31.1%)
|
207.46M
est: 79.97M (+159.4%)
|
82.88M
82.28M – 83.24M
+3.6% YoY
|
90.93M
87.61M – 93.86M
+9.7% YoY
|
105.43M
104.91M – 105.95M
+15.9% YoY
|
114.32M
111.74M – 116.48M
+8.4% YoY
|
127.86M
124.97M – 130.28M
+11.8% YoY
|
| EPS |
9.16
est: 9.02 (+1.5%)
|
10.27
est: 10.50 (-2.2%)
|
7.83
est: 7.42 (+5.5%)
|
10.71
est: 10.86 (-1.4%)
|
11.26
10.61 – 12.00
+3.6% YoY
|
12.56
10.85 – 13.85
+11.6% YoY
|
15.43
14.72 – 16.89
+22.8% YoY
|
16.00
15.53 – 16.39
+3.7% YoY
|
18.00
17.47 – 18.44
+12.5% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-28 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-27 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-26 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-22 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-21 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-20 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-19 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-18 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-13 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-12 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-11 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-08 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-07 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-06 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-05 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-04 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-29 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-28 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-27 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | B | 3/5 | 3/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | B | 3/5 | 3/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares MSCI Denmark ETF EDEN | 0.57% | 1.18M | 0.53% |
| 2 | iShares Healthcare Innovation UCITS ETF HEAL.L | 0.13% | 1.45M | 0.40% |
| 3 | Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Acc CEM.PA | 0.12% | 409.5K | 0.23% |
| 4 | Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Dist X026.DE | 0.12% | 409.5K | 0.23% |
| 5 | WisdomTree Europe SmallCap Dividend UCITS ETF Acc DFEA.L | 0.09% | 81.4K | 0.38% |
| 6 | WisdomTree Europe SmallCap Dividend UCITS ETF WTES.DE | 0.09% | 81.4K | 0.38% |
| 7 | State Street SPDR S&P International Small Cap ETF GWX | 0.08% | 709.2K | 0.40% |
| 8 | iShares MSCI Europe Small-Cap ETF IEUS | 0.07% | 114.8K | 0.41% |
| 9 | Xtrackers MSCI Europe Small Cap UCITS ETF 1C XXSC.L | 0.06% | 2.04M | 0.30% |
| 10 | Avantis International Small Cap Equity ETF AVDS | 0.04% | 139.4K | 0.30% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Martin Helbo Behrens | Chief Executive Officer | 6M | male |
| Kim Nicolajsen | Chief Financial Officer | 3M | male |
| Bo Melholt Nielsen | Chief Technology & Automation Officer | — | male |
| Christopher Runchel | Chief Sales Officer | — | male |
| Emil Sondergaard | Chief Commercial Officer | — | — |
| Søren Kjærulff | Head of R&D | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CHEMM.CO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
